Marketed Products (Unaudited)
Total Product Sales Total net product sales were $3,749 million in 2004, an increase of 43 percent from 2003. The increase was due to higher sales across all products, in particular Avastin™ (bevacizumab), Rituxan® (Rituximab), Xolair® (Omalizumab), Herceptin® (Trastuzumab) and RAPTIVA® (efalizumab) in 2004. Combined sales of our BioOncology products (Rituxan and Herceptin, as well as Avastin and Tarceva™ (erlotinib) in 2004) represented 74 percent of total product sales in 2004 and 73 percent in 2003. Rituxan Net sales of Rituxan were $1,711 million in 2004, a 15 percent increase from 2003. The 2004 growth was driven by increased physician adoption in indolent non-Hodgkin's lymphoma (NHL) maintenance, front-line chronic lymphocytic leukemia, and relapsed aggressive NHL, which are all unapproved uses of Rituxan. Hoffmann-La Roche holds marketing rights for Rituximab outside the United States, excluding Japan. Avastin In 2004, Avastin achieved total net sales of $555 million after launch in late February 2004. Sales were driven primarily by use in colorectal cancer, which represents more than 95 percent of current Avastin use. Our collaborator Hoffmann-La Roche received approval for Avastin in Israel and Switzerland in 2004 and from the European Union in January 2005. Herceptin Net sales of Herceptin were $483 million in 2004, a 14 percent increase from 2003. The growth in 2004 was driven by multiple factors, including physicians' extension of the average treatment duration and increased first-line penetration. In unapproved uses, there continues to be growing adoption by physicians of the combination of Herceptin, carboplatin and taxane, a combination otherwise known as TCH. Hoffmann-La Roche has exclusive marketing rights to Herceptin outside the United States. Growth Hormone Combined net sales of our four growth hormone products, Nutropin AQ® [somatropin (rDNA origin) injection], Nutropin® [somatropin (rDNA origin) for injection], Nutropin Depot® [somatropin (rDNA origin) for injectable suspension], and Protropin® (somatrem for injection), were $354 million in 2004, an increase of 10 percent over 2003. In June 2004, Genentech and collaborator Alkermes decided to discontinue commercialization of Nutropin Depot, with sales expected to cease in 2005. Protropin was discontinued at the end of 2002, and sales ended in late 2004. Thrombolytics Combined net sales of our three thrombolytic products, Activase® (Alteplase), TNKase™ (Tenecteplase) and Cathflo® Activase® (Alteplase), were $200 million in 2004, an increase of 8 percent from 2003. The sales increase in 2004 was driven by a price increase for Activase and growth in our catheter clearance and stroke markets. On January 4, 2005, Cathflo Activase received approval from the U.S. Food and Drug Administration (FDA) for catheter clearance in pediatric patients. Xolair Xolair total net sales were $189 million in 2004 and $25 million in 2003 due to ongoing market penetration reflected by continued acceptance of the product, strong growth in our prescriber base and strong patient compliance. In the second half of 2004, Xolair received regulatory approval in Canada, Brazil, New Zealand, and Venezuela. Our collaborator, Novartis AG, is preparing for Xolair's launch in Canada, Brazil and Venezuela during the first half of 2005. Pulmozyme Net sales of Pulmozyme® (dornase alfa, recombinant) Inhalation Solution were $178 million in 2004, an increase of 6 percent from 2003. These increases primarily reflect an increased focus on aggressive treatment of cystic fibrosis early in the course of the disease and a price increase in 2004. RAPTIVA Net sales of RAPTIVA were $56 million in 2004 and $1 million in 2003, reflecting continued acceptance of the product and effective reimbursement processing. In September 2004, Serono S.A., which has rights to market RAPTIVA in certain areas of the world, announced that it had received European Commission Marketing Authorization for RAPTIVA. As of the end of January 2005, RAPTIVA was registered in the European Union and 12 other countries and was already available in 15 of these countries through our collaborator, Serono. Tarceva On November 18, 2004, the FDA approved Tarceva. Net sales in 2004 were $13 million after launch, reflecting distribution of the product into the supply channel and positive physician adoption rates. |
